Actinium Pharmaceuticals (Delaware) (ATNM) vs Lite Strategy (LITS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Lite Strategy (LITS) over the past year, losing 26.7% versus a loss of 50.0%. Over five years, ATNM leads with a -86.3% price change compared with -97.8% for LITS. Lite Strategy is the larger company by market cap ($38.6 million vs $34.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | LITS |
|---|---|---|
| Share price | $1.10 | $1.27 |
| Market cap | $34.59M | $38.62M |
| 1-day change | +1.85% | +4.10% |
| YTD return | -19.12% | -3.79% |
| 1-year return | -26.67% | -50.00% |
| 5-year return | -86.32% | -97.82% |
| P/E ratio (TTM) | 3.06 | — |
| EPS (TTM) | $0.36 | $-2.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.74 | $2.97 |
| 52-week low | $0.735 | $0.69 |
| Distance from 52-week high | -36.78% | -57.24% |
| Analyst consensus | none | — |
| Avg. price target upside | +227.27% | — |
| Average volume | 139.78K | 462.76K |
| Shares outstanding | 31.44M | 30.41M |
| Employees | 27 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed LITS by 23.3 percentage points over the past year.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Lite Strategy
LITS stock →Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ATNM vs LITS FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or Lite Strategy?
Lite Strategy (LITS) is larger, with a market capitalization of $38.62M compared with $34.59M for Actinium Pharmaceuticals (Delaware) (ATNM).
Which stock has performed better over the past year, ATNM or LITS?
ATNM returned -26.67% over the past 12 months, compared with -50.00% for LITS (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and Lite Strategy in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.